181 related articles for article (PubMed ID: 32869095)
1. A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma.
Harada H; Shikama N; Wada H; Uchida N; Nozaki M; Hayakawa K; Yamada K; Nagakura H; Ogawa H; Miyazawa K; Katagiri H; Nakamura N
Jpn J Clin Oncol; 2021 Jan; 51(1):100-105. PubMed ID: 32869095
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up.
Takeda N; Isu K; Hiraga H; Shinohara N; Minami A; Kamata H
J Orthop Sci; 2012 Nov; 17(6):770-4. PubMed ID: 23053582
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Lipton A; Zheng M; Seaman J
Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
[TBL] [Abstract][Full Text] [Related]
4. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
5. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Lipton A; Colombo-Berra A; Bukowski RM; Rosen L; Zheng M; Urbanowitz G
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
[TBL] [Abstract][Full Text] [Related]
6. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
7. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
Broom RJ; Hinder V; Sharples K; Proctor J; Duffey S; Pollard S; Fong PC; Forgeson G; Harris DL; Jameson MB; O'Donnell A; North RT; Deva S; Hanning FJ; Grey A; Findlay MP
Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
[TBL] [Abstract][Full Text] [Related]
8. Concomitant radiotherapy and transarterial chemoembolization reduce skeletal-related events related to bone metastases from renal cell carcinoma.
Heianna J; Makino W; Ariga T; Ishikawa K; Kusada T; Maemoto H; Toguchi M; Ito J; Goya M; Miyazato M; Iraha Y; Murayama S
Eur Radiol; 2020 Mar; 30(3):1525-1533. PubMed ID: 31728686
[TBL] [Abstract][Full Text] [Related]
9. Skeletal complications and survival in renal cancer patients with bone metastases.
Woodward E; Jagdev S; McParland L; Clark K; Gregory W; Newsham A; Rogerson S; Hayward K; Selby P; Brown J
Bone; 2011 Jan; 48(1):160-6. PubMed ID: 20854942
[TBL] [Abstract][Full Text] [Related]
10. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
[TBL] [Abstract][Full Text] [Related]
11. Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation.
Brinkmann OA; Bruns F; Gosheger G; Micke O; Hertle L
World J Urol; 2005 Jul; 23(3):185-90. PubMed ID: 15838689
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma.
Lee J; Hodgson D; Chow E; Bezjak A; Catton P; Tsuji D; O'Brien M; Danjoux C; Hayter C; Warde P; Gospodarowicz MK
Cancer; 2005 Nov; 104(9):1894-900. PubMed ID: 16177996
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis.
Hosaka S; Katagiri H; Niwakawa M; Harada H; Wasa J; Murata H; Takahashi M
Int J Clin Oncol; 2018 Dec; 23(6):1127-1133. PubMed ID: 29959563
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
15. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.
Yasuda Y; Fujii Y; Yuasa T; Kitsukawa S; Urakami S; Yamamoto S; Yonese J; Takahashi S; Fukui I
Int J Clin Oncol; 2013 Oct; 18(5):877-83. PubMed ID: 22965827
[TBL] [Abstract][Full Text] [Related]
16. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
17. The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma.
Wilson D; Hiller L; Gray L; Grainger M; Stirling A; James N
Clin Oncol (R Coll Radiol); 2003 Oct; 15(7):400-7. PubMed ID: 14570088
[TBL] [Abstract][Full Text] [Related]
18. Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases.
Tam AH; Schepers AJ; Qin A; Nachar VR
Ann Pharmacother; 2021 Jun; 55(6):697-704. PubMed ID: 33070623
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yamamoto S; Masuda H; Yonese J; Fukui I
BJU Int; 2009 Mar; 103(5):620-4. PubMed ID: 18990143
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]